1. Home
  2. HOFT vs IMUX Comparison

HOFT vs IMUX Comparison

Compare HOFT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hooker Furnishings Corporation

HOFT

Hooker Furnishings Corporation

HOLD

Current Price

$13.30

Market Cap

144.6M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.87

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOFT
IMUX
Founded
1924
2016
Country
United States
United States
Employees
N/A
66
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
144.6M
152.6M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
HOFT
IMUX
Price
$13.30
$0.87
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$4.50
AVG Volume (30 Days)
30.4K
2.6M
Earning Date
04-16-2026
05-14-2026
Dividend Yield
3.68%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$278,139,000.00
N/A
Revenue This Year
$17.37
N/A
Revenue Next Year
$9.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.46
$0.51
52 Week High
$15.99
$1.51

Technical Indicators

Market Signals
Indicator
HOFT
IMUX
Relative Strength Index (RSI) 47.37 35.61
Support Level $9.27 $0.78
Resistance Level $13.47 $0.88
Average True Range (ATR) 0.98 0.10
MACD -0.13 -0.04
Stochastic Oscillator 26.43 3.99

Price Performance

Historical Comparison
HOFT
IMUX

About HOFT Hooker Furnishings Corporation

Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: